The necessity of adjuvant surgery for patients with high-risk chemorefractory or relapsed gestational choriocarcinoma with complete remission after anti-PD-1 therapy
These results suggest that surgical resection of drug-resistant lesions may not be necessary in patients with high-risk chemorefractory or relapsed choriocarcinoma who achieve CR after anti-PD-1 therapy.
Authors
- Yonglan He (ORCID: https://orcid.org/0000-0003-2567-9710)
- Xirun Wan (ORCID: https://orcid.org/0000-0002-1688-298X)
- Jiayuan Zhao (ORCID: https://orcid.org/0000-0002-1105-6208)
- Dan Wang (ORCID: https://orcid.org/0000-0003-1287-404X)
- Yang Xiang (ORCID: https://orcid.org/0000-0002-9112-1021)
- Jun Zhao (ORCID: https://orcid.org/0000-0002-9460-6796)
- Junjun Yang (ORCID: https://orcid.org/0000-0002-5625-0119)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Journal of Gynecologic Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.3802/jgo.2025.36.e130
- Primary Topic
- Gestational Trophoblastic Disease Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Peking Union Medical College Hospital
- National Key Research and Development Program of China